USP Negative Ephedra Monograph To Follow FDA Final Action

The United States Pharmacopeia plans to create a negative monograph for ephedra following FDA action on the dietary supplement ingredient, CEO Jerome Halperin said at a meeting of the USP Ad Hoc Panel on Botanicals in Rockville, Md. Nov. 8.